These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8476219)

  • 21. Applicability of monoclonal antibody Fab fragments as a carrier of neocarzinostatin in targeting chemotherapy.
    Otsuji E; Yamaguchi T; Tsuruta H; Yata Y; Nishi H; Okamoto K; Taniguchi K; Kato M; Kotani T; Kitamura K; Takahashi T
    J Surg Oncol; 1996 Feb; 61(2):149-54. PubMed ID: 8606548
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
    Colcher D; Pavlinkova G; Beresford G; Booth BJ; Choudhury A; Batra SK
    Q J Nucl Med; 1998 Dec; 42(4):225-41. PubMed ID: 9973838
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune responses in patients with T-cell lymphoma treated with an anti-idiotype antibody mimicking a highly restricted T-cell antigen.
    Foon KA; Oseroff AR; Vaickus L; Greenberg SJ; Russell D; Bernstein Z; Pincus S; Köhler H; Seon BK; Tahaoglu E
    Clin Cancer Res; 1995 Nov; 1(11):1285-94. PubMed ID: 9815923
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The human antimouse immunoglobulin response and the anti-idiotypic network have no influence on clinical outcome in patients with minimal residual colorectal cancer treated with monoclonal antibody CO17-1A.
    Gruber R; van Haarlem LJ; Warnaar SO; Holz E; Riethmüller G
    Cancer Res; 2000 Apr; 60(7):1921-6. PubMed ID: 10766181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Humoral immune responses induced by anti-idiotypic antibody fusion protein of 6B11scFv/hGM-CSF in BALB/c mice.
    Chang XH; Ye X; Cui H; Feng J; Li Y; Zhu HL; Yang WL; Fu TY; Cheng HY; Guo HF
    Chin Med J (Engl); 2006 Jan; 119(2):131-9. PubMed ID: 16454995
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of anticytokeratin monoclonal anti-idiotypic antibodies to improve tumor:nontumor ratio in experimental radioimmunolocalization.
    Ullén A; Sandström P; Ahlström KR; Sundström B; Nilsson B; Arlestig L; Stigbrand T
    Cancer Res; 1995 Dec; 55(23 Suppl):5868s-5873s. PubMed ID: 7493362
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The influence of syngeneic anti-idiotypic antibody on the biodistribution of an anti-tumour monoclonal antibody in BALB/c mice.
    Pimm MV; Durrant LG; Baldwin RW
    Int J Cancer; 1989 Jan; 43(1):147-51. PubMed ID: 2783414
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Possible consequences of human antibody responses on the biodistribution of fragments of human, humanized or chimeric monoclonal antibodies: a note of caution.
    Pimm MV
    Life Sci; 1994; 55(2):PL45-9. PubMed ID: 8015352
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of L6, an anti-carcinoma murine monoclonal antibody, in tumor-bearing nude mice.
    Lavie E; Beaumier PL; Brodzinsky L; Hellström KE; Hellström I
    Radiother Oncol; 1989 Jul; 15(3):295-305. PubMed ID: 2772257
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improvement by affinity chromatography on antiidiotypic monoclonal antibodies (MAbs) of immunoreactivity and in vivo targeting of radiolabelled anti-HMW-MAA MAb TP61.5 in nude mice bearing human melanoma lesions.
    Temponi M; Fawwaz RA; Kekish U; Wang TS; Ferrone S
    Int J Cancer; 1991 Oct; 49(4):624-30. PubMed ID: 1917164
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differences between the catabolism and tumour distribution of intact monoclonal antibody (791T/36) and its Fab/c fragment in mice with tumour xenografts revealed by the use of a residualizing radiolabel (dilactitol-125I-tyramine) and autoradiography.
    Demignot S; Pimm MV; Thorpe SR; Baldwin RW
    Cancer Immunol Immunother; 1991; 33(6):359-66. PubMed ID: 1878889
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetic studies of radiolabelled rat monoclonal antibodies recognising syngeneic sarcoma antigens. II. Effect of host age and immune status.
    Eccles SA; Purvies HP; Styles JM; Hobbs SM; Dean CJ
    Cancer Immunol Immunother; 1989; 30(1):13-20. PubMed ID: 2598171
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of recombinant tumour necrosis factor alpha on blood flow and antibody localisation in human tumour xenografts in nude mice.
    Pimm MV; Gribben SJ; Morris TM
    J Cancer Res Clin Oncol; 1991; 117(6):543-8. PubMed ID: 1744160
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of monoclonal idiotypic-specific antibodies as clearing antibodies for enhancement of target localisation by tumour-specific monoclonal antibodies: diversity of effects in nude mice with human tumour xenografts.
    Pimm MV; Gribben SJ
    Eur J Nucl Med; 1992; 19(6):436-40. PubMed ID: 1618235
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Selective localisation of two radiolabelled anti-sarcoma monoclonal antibodies in human osteosarcoma xenografts.
    Bruland O; Fodstad O; Skretting A; Pihl A
    Br J Cancer; 1987 Jul; 56(1):21-5. PubMed ID: 3476143
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Radioimmunolocalisation of bladder tumors xenotransplanted in nude mice.
    Hansson Y; Paulie S; Ben-Aïssa H; Rudberg U; Karlsson A; Perlmann P
    Anticancer Res; 1988; 8(3):435-41. PubMed ID: 3389745
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthetic polymers conjugated to monoclonal antibodies: vehicles for tumour-targeted drug delivery.
    Seymour LW; Flanagan PA; al-Shamkhani A; Subr V; Ulbrich K; Cassidy J; Duncan R
    Sel Cancer Ther; 1991; 7(2):59-73. PubMed ID: 1754729
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor localization of monoclonal antibodies against human renal carcinoma in a xenograft model.
    Guha AK; Ghose T; Singh M; Aquino J; Blair AH; Luner SJ; Mammen M
    Cancer Lett; 1991 Dec; 61(1):35-43. PubMed ID: 1764696
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic studies of radiolabelled rat monoclonal antibodies recognising syngeneic sarcoma antigens. I. Comparison of IgG subclasses.
    Eccles SA; Purvies HP; Styles JM; Hobbs SM; Dean CJ
    Cancer Immunol Immunother; 1989; 30(1):5-12. PubMed ID: 2598175
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Syngeneic anti-idiotypic antibodies eliminate excess radiolabeled idiotypes at experimental radioimmunolocalization.
    Ullén A; Riklund Ahlström K; Makiya R; Stigbrand T
    Cell Biophys; 1995 Aug; 27(1):31-45. PubMed ID: 7493397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.